X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213195
https://www.prnewswire.com/news-releases/janone-files-international-patent-application-for-methods-of-using-low-dose-naltrexone-to-treat-chronic-pain-301865422.html
https://www.globenewswire.com/news-release/2022/10/13/2533867/0/en/BioCorRx-Completes-Final-Subject-Enrollment-in-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treatment-of-Opioid-Use-Disorder.html
https://www.globenewswire.com/news-release/2022/10/06/2529493/0/en/Opiant-Pharmaceuticals-Announces-Completion-of-Enrollment-in-Phase-2-Clinical-Trial-of-OPNT002-Nasal-Naltrexone-in-Patients-with-Alcohol-Use-Disorder.html
https://www.globenewswire.com/news-release/2022/06/30/2472213/0/en/BioCorRx-Announces-First-Subject-Dosed-in-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treatment-of-Opioid-Use-Disorder.html
https://www.globenewswire.com/news-release/2022/04/27/2430707/0/en/Statera-Biopharma-and-Immune-Therapeutics-Inc-Announce-Strategic-Agreement-for-Rights-to-Low-Dose-Naltrexone.html
https://www.globenewswire.com/news-release/2022/01/20/2370646/37234/en/Opiant-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-2-Trial-of-OPNT002-Nasal-Naltrexone-for-Alcohol-Use-Disorder.html
https://www.globenewswire.com/news-release/2021/09/22/2301321/0/en/BioCorRx-Files-Patent-Application-with-USPTO-for-Naltrexone-Implant.html
https://www.painnewsnetwork.org/stories/2021/9/20/low-dose-naltrexone-being-studied-as-treatment-for-crps
https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-status-to-soin-therapeutics-for-low-dose-naltrexone-ldn-to-treat-complex-regional-pain-syndrome-crps-301372111.html
https://www.prnewswire.com/news-releases/campbell-neurosciences-spin-off-of-therapeutic-solutions-reports-synergistic-reduction-of-schizophrenia-in-animal-models-using-low-dose-naltrexone-and-t-regulatory-cell-stimulation-301313738.html
https://www.prnewswire.com/news-releases/nida-funded-study-evaluating-extended-release-injectable-naltrexone-plus-bupropion-for-the-treatment-of-methamphetamine-use-disorder-published-in-new-england-journal-of-medicine-301208061.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-vivitrol-21897-naltrexone380-mgvial-1597495007.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-5-2020-1580878802.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-9-2019-1570607610.pdf
https://www.clinicaltrialsarena.com/news/wistar-opioid-use-research-hiv-patients/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-4-2019-1567563406.pdf
https://www.gov.uk/drug-safety-update/naltrexone-bupropion-mysimba-risk-of-adverse-reactions-that-could-affect-ability-to-drive
https://www.prnewswire.com/news-releases/alkermes-announces-settlement-with-amneal-over-vivitrol-patent-dispute-300892397.html
https://www.reuters.com/article/us-indivior-genericdrugs-dr-reddys/indivior-wins-fresh-hold-on-dr-reddys-suboxone-copy-idUSKBN1OB0OG
https://www.forbes.com/sites/joshuacohen/2018/09/10/belviq-study-results-may-improve-the-fortunes-of-weight-loss-drugs/#2cefd3836a40
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-25-2018-1524633895.pdf
https://www.statnews.com/2018/03/26/trump-opioid-plan-alkermes-vivitrol/
https://endpts.com/in-a-blow-to-its-biggest-revenue-driver-indivior-loses-patent-battle-with-generics-maker-alvogen/
https://www.vox.com/policy-and-politics/2018/3/13/17020002/prison-opioid-epidemic-medications-addiction
http://www.nwaonline.com/news/2018/feb/26/fda-to-boost-drug-therapy-for-addicts-2/?news-national
http://www.pharmatimes.com/news/final_nhs_no_for_obesity_pill_mysimba_1214102
http://www.pharmatimes.com/news/nice_bars_obesity_pill_from_routine_nhs_use_1199805
http://www.in-pharmatechnologist.com/Drug-Delivery/Elite-halts-reformulated-SequestOx-studies-after-BE-data-falls-short
https://directorsblog.nih.gov/2017/05/31/all-scientific-hands-on-deck-to-end-the-opioid-crisis/
http://www.pharmatimes.com/news/nice_rejects_orexigens_weight-loss_pill_1192361
https://globenewswire.com/news-release/2017/04/17/961333/0/en/Immune-Therapeutics-Clears-Critical-Regulatory-Hurdle-for-Lodonal-in-Kenya.html
http://www.pharmatimes.com/news/pfizers_abuse-deterrent_opioid_bags_us_nod_1106601
http://www.forbes.com/sites/cjarlotta/2016/03/31/naltrexone-diminishes-opioid-relapse-rates-in-ex-convicts/#42edeb805f9c
http://cphi-online.com/future-obesity-drugs-must-provide-improved-news038407.html
http://health.economictimes.indiatimes.com/news/pharma/french-drug-developer-pharnext-to-take-rare-approach-to-pricing/50200904
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003687/WC500185583.pdf
http://www.pharmatimes.com/Article/15-03-26/Europe_approves_Orexigen_s_weight-loss_pill_Mysimba.aspx
http://www.prnewswire.com/news-releases/immune-therapeutics-inc-announces-agreement-with-krs-global-biotechnology-inc-300024763.html
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/12/news_detail_002239.jsp&mid=WC0b01ac058004d5c1
Market Place
Share 
